- Home
- ATCX vs INAB Comparison
ATCX vs INAB Comparison
Compare ATCX & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATCX | INAB |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | Brazil | United States |
| Employees | 13 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 22.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATCX | INAB |
|---|---|---|
| Price | $4.97 | $1.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 35.1K | ★ 66.2K |
| Earning Date | 03-16-2023 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,654,115.00 | N/A |
| Revenue Next Year | $33.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.65 | $0.12 |
| 52 Week High | $14.01 | $4.20 |
Technical Indicators
Market Signals| Indicator | ATCX | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 38.05 | 36.83 |
| Support Level | $4.65 | $1.17 |
| Resistance Level | $5.44 | $2.59 |
| Average True Range (ATR) | 0.49 | 0.20 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 6.72 | 6.58 |
Price Performance
Historical ComparisonAbout ATCX Atlas Critical Minerals Corporation Common Stock
Atlas Critical Minerals Corp is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.